Epigenetic modifications: Key players in cancer heterogeneity and drug resistance

Hana Q. Sadida; Alanoud Abdulla; Sara Al Marzooqi; Sheema Hashem; Muzafar A. Macha; Ammira S. Al-Shabeeb Akil; Ajaz A. Bhat

doi:10.1016/j.tranon.2023.101821

journal article Open Access Jan 01, 2024

Epigenetic modifications: Key players in cancer heterogeneity and drug resistance

Hana Q. Sadida

Alanoud Abdulla Sara Al Marzooqi

Sheema Hashem Muzafar A. Macha

Ammira S. Al-Shabeeb Akil Ajaz A. Bhat

Translational Oncology Vol. 39 pp. 101821 · Elsevier BV

View at Publisher Save 10.1016/j.tranon.2023.101821

Topics

No keywords indexed for this article. Browse by subject →

References

181

[1]

Jones "Targeting the cancer epigenome for therapy" Nat. Rev. Genet. (2016) 10.1038/nrg.2016.93

[2]

Sharma "Epigenetics in cancer" Carcinogenesis (2010) 10.1093/carcin/bgp220

[3]

Hallmarks of Cancer: The Next Generation

Douglas Hanahan, Robert A. Weinberg

Cell 2011 10.1016/j.cell.2011.02.013

[4]

Burrell "The causes and consequences of genetic heterogeneity in cancer evolution" Nature (2013) 10.1038/nature12625

[5]

McGranahan "Clonal heterogeneity and tumor evolution: past, present, and the future" Cell (2017) 10.1016/j.cell.2017.01.018

[6]

Alizadeh "Toward understanding and exploiting tumor heterogeneity" Nat. Med. (2015) 10.1038/nm.3915

[7]

Holohan "Cancer drug resistance: an evolving paradigm" Nat. Rev. Cancer (2013) 10.1038/nrc3599

[8]

Hangauer "Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition" Nature (2017) 10.1038/nature24297

[9]

Epigenetic modulators, modifiers and mediators in cancer aetiology and progression

Andrew P. Feinberg, Michael A. Koldobskiy, Anita Göndör

Nature Reviews Genetics 2016 10.1038/nrg.2016.13

[10]

Flavahan "Epigenetic plasticity and the hallmarks of cancer" Science (2017) 10.1126/science.aal2380

[11]

Chi "Covalent histone modifications–miswritten, misinterpreted and mis-erased in human cancers" Nat. Rev. Cancer (2010) 10.1038/nrc2876

[12]

Easwaran "Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance" Mol. Cell (2014) 10.1016/j.molcel.2014.05.015

[13]

Ahmed "Epigenetic tumor heterogeneity in the era of single-cell profiling with nanopore sequencing" Clin. Epigenetics (2022) 10.1186/s13148-022-01323-6

[14]

Dawson "Cancer epigenetics: from mechanism to therapy" Cell (2012) 10.1016/j.cell.2012.06.013

[15]

Esteller "Epigenetics in cancer" N. Engl. J. Med. (2008) 10.1056/nejmra072067

[16]

Haven "Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations" eLife (2016) 10.7554/elife.09462

[17]

You "Cancer genetics and epigenetics: two sides of the same coin?" Cancer Cell (2012) 10.1016/j.ccr.2012.06.008

[18]

Terranova-Barberio "Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors" Immunotherapy (2016) 10.2217/imt-2016-0014

[19]

Chi "Long non-coding RNA in the pathogenesis of cancers" Cells (2019) 10.3390/cells8091015

[20]

Portela "Epigenetic modifications and human disease" Nat. Biotechnol. (2010) 10.1038/nbt.1685

[21]

Hamilton "Epigenetics: principles and practice" Dig. Dis. (2011) 10.1159/000323874

[22]

Handy "Epigenetic modifications: basic mechanisms and role in cardiovascular disease" Circulation (2011) 10.1161/circulationaha.110.956839

[23]

Carter "The epigenetic basis of cellular heterogeneity" Nat. Rev. Genet. (2021) 10.1038/s41576-020-00300-0

[24]

Moore "DNA methylation and its basic function" Neuropsychopharmacology (2013) 10.1038/npp.2012.112

[25]

Canovas "DNA methylation in embryo development: epigenetic impact of ART (Assisted Reproductive Technologies)" Bioessays (2017)

[26]

Siegfried "DNA methylation and gene expression" Wiley Interdiscip. Rev. Syst. Biol. Med. (2010) 10.1002/wsbm.64

[27]

Alaskhar Alhamwe "Histone modifications and their role in epigenetics of atopy and allergic diseases" Allergy Asthma Clin. Immunol. (2018) 10.1186/s13223-018-0259-4

[28]

Crystal structure of the nucleosome core particle at 2.8 Å resolution

Karolin Luger, Armin W. Mäder, Robin K. Richmond et al.

Nature 1997 10.1038/38444

[29]

Audia "Histone modifications and cancer" Cold Spring Harb. Perspect. Biol. (2016) 10.1101/cshperspect.a019521

[30]

Zhang "Overview of histone modification" Adv. Exp. Med. Biol. (2021) 10.1007/978-981-15-8104-5_1

[31]

Bannister "Regulation of chromatin by histone modifications" Cell Res. (2011) 10.1038/cr.2011.22

[32]

Martin "Mechanisms of epigenetic inheritance" Curr. Opin. Cell Biol. (2007) 10.1016/j.ceb.2007.04.002

[33]

Tan "Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification" Cell (2011) 10.1016/j.cell.2011.08.008

[34]

Herranz "Lysyl oxidase-like 2 deaminates lysine 4 in histone H3" Mol. Cell (2012) 10.1016/j.molcel.2012.03.002

[35]

Tweedie-Cullen "Identification of combinatorial patterns of post-translational modifications on individual histones in the mouse brain" PLoS One (2012) 10.1371/journal.pone.0036980

[36]

Kouzarides "Chromatin modifications and their function" Cell (2007) 10.1016/j.cell.2007.02.005

[37]

McBrian "Histone acetylation regulates intracellular pH" Mol. Cell (2013) 10.1016/j.molcel.2012.10.025

[38]

Di Cerbo "Cancers with wrong HATs: the impact of acetylation" Brief. Funct. Genomic. (2013) 10.1093/bfgp/els065

[39]

De Bakshi "Mirizzi syndrome in a patient with carcinoma of the gallbladder" Br. J. Surg. (1992) 10.1002/bjs.1800790430

[40]

Seligson "Global levels of histone modifications predict prognosis in different cancers" Am. J. Pathol. (2009) 10.2353/ajpath.2009.080874

[41]

Baylin "Epigenetic determinants of cancer" Cold Spring Harb. Perspect. Biol. (2016) 10.1101/cshperspect.a019505

[42]

Barneda-Zahonero "Histone deacetylases and cancer" Mol. Oncol. (2012) 10.1016/j.molonc.2012.07.003

[43]

Busslinger "Epigenetic control of immunity" Cold Spring Harb. Perspect. Biol. (2014) 10.1101/cshperspect.a019307

[44]

Kaikkonen "Non-coding RNAs as regulators of gene expression and epigenetics" Cardiovasc. Res. (2011) 10.1093/cvr/cvr097

[45]

Mercer "Long non-coding RNAs: insights into functions" Nat. Rev. Genet. (2009) 10.1038/nrg2521

[46]

Yang "Non-coding RNAs: an introduction" Adv. Exp. Med. Biol. (2016) 10.1007/978-94-017-7417-8_2

[47]

Yan "Non-coding RNA in cancer" Essays Biochem. (2021) 10.1042/ebc20200032

[48]

Kimura "[Non-coding Natural Antisense RNA: mechanisms of action in the regulation of target gene expression and its clinical implications]" Yakugaku Zasshi (2020) 10.1248/yakushi.20-00002

[49]

Na "MicroRNA-155 contributes to plexiform neurofibroma growth downstream of MEK" Oncogene (2021) 10.1038/s41388-020-01581-9

[50]

Jin "Let-7 inhibits self-renewal of hepatocellular cancer stem-like cells through regulating the epithelial-mesenchymal transition and the Wnt signaling pathway" BMC Cancer (2016) 10.1186/s12885-016-2904-y

Showing 50 of 181 references

Cited By

108

Tubulin polymerization inhibitors in early clinical studies as cancer therapeutics

Ahmed Kamal, Rahaman Shaik · 2026

Expert Opinion on Investigational D...

Cytokine epigenetics network for gastric cancer progression and chemoresistance

Ganji Purnachandra Nagaraju, Seema Kumari · 2026

Pharmacological Research

Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches

Muhammad Tufail, Can-Hua Jiang · 2025

Signal Transduction and Targeted Th...

Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer

Jennifer Haynes, Prasath Manogaran · 2025

International Journal of Molecular...

Coptisine enhances the sensitivity of chemoresistant breast cancer cells by inhibiting the function and expression of ABC transporters

Safaa Yehia Eid · 2024

Frontiers in Pharmacology

Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells

Jyoti Malhotra, Prakash Kulkarni · 2024

Cancers

Metrics

108

Citations

181

References

Details

Published: Jan 01, 2024
Vol/Issue: 39
Pages: 101821
License: View

Authors

Ammira S. Al-Shabeeb Akil

A

Ajaz A. Bhat

Funding

Qatar National Library

Cite This Article

Hana Q. Sadida, Alanoud Abdulla, Sara Al Marzooqi, et al. (2024). Epigenetic modifications: Key players in cancer heterogeneity and drug resistance. Translational Oncology, 39, 101821. https://doi.org/10.1016/j.tranon.2023.101821

Epigenetic modifications: Key players in cancer heterogeneity and drug resistance

You May Also Like